🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million new cases each year. Especially elevated rates are reported in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the face of rising global incidence, the spread of superbugs and the highly restricted therapeutic options currently available.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in concurrent days. This drug, which is employed against UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization represents a significant shift in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

As per findings published in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This establishes an equal footing with the current standard treatment, which involves two antibiotics. The research involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in many developing nations.

Medical professionals on the front lines have expressed optimism. The availability of a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for managing the epidemic. This is deemed vital to alleviate the strain of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.